Keyphrases
Meta-analysis
100%
Systematic Meta-analysis
100%
Randomized Trial
100%
Maintenance Treatment
100%
Mantle Cell Lymphoma
100%
Rituximab Maintenance
75%
Maintenance Therapy
50%
Hazard Ratio
50%
R-CHOP
50%
Transplant Eligibility
50%
Treatment Group
25%
Infection Rate
25%
Current Treatment
25%
Risk Ratio
25%
Meta-analysis of Randomized Controlled Trials
25%
Cytarabine
25%
Neutropenia
25%
Lymphoma Patients
25%
Pooled Analysis
25%
Progression-free Survival
25%
Rituximab
25%
Bendamustine
25%
Fludarabine
25%
Induction Chemotherapy
25%
Quality of Life Outcomes
25%
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
100%
Maintenance Therapy
100%
Mantle Cell Lymphoma
100%
Rituximab
100%
Hazard Ratio
50%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
50%
Group Therapy
25%
Quality of Life
25%
Infection
25%
Randomized Controlled Trial
25%
Transplantation
25%
Infection Rate
25%
Neutropenia
25%
Pooled Analysis
25%
Progression Free Survival
25%
Induction Chemotherapy
25%
Cytarabine
25%
Fludarabine
25%
Bendamustine
25%
Nursing and Health Professions
Meta Analysis
100%
Hospital Service
100%
Systematic Review
100%
Maintenance Therapy
100%
Mantle Cell Lymphoma
100%
Rituximab
57%
Hazard Ratio
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Infection
14%
Quality of Life
14%
Transplantation
14%
Infection Rate
14%
Neutropenia
14%
Group Therapy
14%
Progression Free Survival
14%
Bendamustine
14%
Fludarabine
14%
Induction Chemotherapy
14%
Cytarabine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
100%
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
50%
Infection
25%
Chemotherapy
25%
Randomized Controlled Trial
25%
Infection Rate
25%
Cytarabine
25%
Neutropenia
25%
Progression Free Survival
25%
Bendamustine
25%
Fludarabine
25%
Immunology and Microbiology
Lymphoma Cell
100%
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
50%
Transplant Procedure
25%
Infection Rate
25%
Progression Free Survival
25%